Advanced search
Publication Cover
Postgraduate Medicine Volume 132, 2020 - Issue sup2: Supplement: Introducing oral semaglutide and the PIONEER program to primary care
Submit an article Journal homepage
1,029
Views
0
CrossRef citations to date
0
Altmetric
Supplement: introducing oral semaglutide and the PIONEER program to primary care

Introducing a novel therapy for type 2 diabetes to primary care

Stephen A. BruntonTouro University California, Vallejo, CA, USACorrespondence[email protected]
View further author information
Pages 1-2 | Received 17 Jul 2020, Accepted 17 Jul 2020, Published online: 08 Sep 2020

References

  • Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25–32.
  • Davidson JA. The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010;85(12 Suppl):S3–S4.
  • National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes in America. 3rd ed. 2018. Chapter 3 [cited 2020 May 25]. Available from: https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/diabetes-in-america-3rd-edition
  • Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.
  • American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(Suppl 1):S37–S47.
  • American Diabetes Association. 12. Older adults: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(Suppl 1):S152–S162.
  • American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(Suppl 1):S98–S110.
  • Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26:107–139.
  • Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487–493.
  • American Diabetes Association. 1. Improving care and promoting health in populations: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(Suppl 1):S7–S12.
  • Carls G, Huynh J, Tuttle E, et al. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther. 2017;8(4):863–873.
  • Cowie CC. Diabetes diagnosis and control: missed opportunities to improve health: the 2018 Kelly West Award lecture. Diabetes Care. 2019;42(6):994–1004.
  • Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019;10:2042018819844694.
  • Nelson LA, Wallston KA, Kripalani S, et al. Assessing barriers to diabetes medication adherence using the Information-Motivation-Behavioral skills model. Diabetes Res Clin Pract. 2018;142:374–384.
  • Aroda VR. A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab. 2018;20(Suppl 1):22–33.
  • Chatterjee S, Davies MJ, Khunti K. What have we learnt from “real world” data, observational studies and meta-analyses. Diabetes Obes Metab. 2018;20(Suppl 1):47–58.
  • Levin PA, Nguyen H, Wittbrodt ET, et al. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes. 2017;10:123–139.
  • Rybelsus® (semaglutide) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213182s000,213051s001lbl.pdf
  • Santos Cavaiola T, Kiriakov Y, Reid T. Primary care management of patients with type 2 diabetes: overcoming inertia and advancing therapy with the use of injectables. Clin Ther. 2019;41:352–367.
  • Schmieder RE, Tschöpe D, Koch C, et al. Individualised treatment targets in patients with type-2 diabetes and hypertension. Cardiovasc Diabetol. 2018;17(1):18.
  • Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96(6):414–422D.
  • Gregg EW, Cheng YJ, Srinivasan M, et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet. 2018;391(10138):2430–2440.
  • Taylor KS, Heneghan CJ, Farmer AJ, et al. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care. 2013;36(8):2366–2371.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.